ResiquimodPOx-RCAR T-cell therapymedulloblastomaG3MBB7-H3-directed CAR T-cell therapy
…nflammatory TAMs can support CAR T-cell function. We identified Resiquimod, a Toll-like receptor (TLR) 7/8 agonist, as a potent immunomodu…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 541–600 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
N-Acetyl Cysteine7PPIs7Streptozotocin7fondaparinux7high-dose corticosteroids7hydroxyurea7naltrexone7tyrosine kinase inhibitors7vaccines7SGLT-2i6Glipizide6BLV6Varenicline6Camrelizumab6Cancer Drugs6Benzene6Doxy-PEP6SGLT-2is6Aprepitant6DEX6Dostarlimab6T-DXd6Azacitidine6Esketamine6NAC6Fidaxomicin6ITM6Minocycline6N-acetylcysteine6pMDIs6NBCA6Clofazimine6Filgotinib6Ravulizumab6Atomoxetine6Methylphenidate6amoxicillin-clavulanate6Acetylcysteine6Triamcinolone6anti-PD16Nitrous oxide6Octreotide6injectate6IL-1β6Lenalidomide6OAC6Venetoclax6antihypertensive drugs6n-BCA6Anti-TNF6Golimumab6Placebo6aripiprazole6b/tsDMARDs6Lansoprazole6MDPV6Mitomycin C6Nalbuphine6PCSK9 inhibitors6Sodium-Glucose Co-Transporter 2 Inhibitors6
Articles mentioning drugs
10,506 articles · page 303 of 876pegenzileukinmonoclonal antibodieshuman IL-15hematological malignanciesaccredited facility
…γ receptors. This combination of NK cell adoptive transfer with pegenzileukin treatment resulted in remarkable enhancement of NK cell persist…
Neo4Neo4-conjugatedACTblood cancerssolid tumorsChimeric antigen receptor (CAR) T cell therapyScripps Research InstituteScripps Animal Care and Use Programadoptive T cell therapy
…ssion and sustained antitumor responses (figure 2). Remarkably, Neo4 conjugation not only enhanced the efficacy of ACT but also redu…
ipilimumabnivolumabDNAJ-PKAcFibrolamellar carcinoma (FLC)Johns Hopkins IRBT Cell Receptor (TCR)-Based cellular therapy
…combination with the immune checkpoint inhibitors nivolumab and ipilimumab. We analyzed PBMCs from a subset of patients who demonstrated a…
TK-6302
…nor material representing the intended clinical product.Results TK-6302 contained 39-48% TCR negative T cells (knock out) and 24-42% PR…
AZD0240colorectal cancerpancreatic cancerPDACCRChuman cancerTCR-T cell therapy
…reatment of solid cancers, including PDAC and CRC, we developed AZD0240, a CRISPR-engineered autologous TCR-T cell product targeting KR…
CAR-TILmelanomaInstitutional Review Boardsolid tumors
…ly results, we will further define the therapeutic potential of CAR-TIL and will evaluate their therapeutic value for clinical translat…
lifileucelmelanoma
…eried to evaluate post-marketing adverse events associated with lifileucel. All reports submitted from initial market availability through…
DISP-10DV-10solid tumors
…ts. Here we describe a novel two-component therapeutic regimen, DISP-10, which consists of a tumor specific and intravenously administe…
nivolumabdurvalumabtislelizumabatezolizumabpembrolizumabnon-small cell lung cancermelanomapneumonitisImmune checkpoint inhibitorsFDA-approved
…experienced severe reactions. The five most reported drugs were nivolumab (92,753; 44.4%), pembrolizumab (62,096; 29.7%), atezolizumab (3…
OSU-ERβ-12colorectal cancernon-small-cell lung cancerbreast cancerrenal cell carcinoma
…d with anti-tumor effects.9 10 Methods In this study, we employ OSU-ERβ-12, a potent, carborane-based molecule that can selectively target…